Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Sevelamer on P-cresyl Sulfate in CKD

Next Previous
Search
Trial Profile

Effect of Sevelamer on P-cresyl Sulfate in CKD

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sevelamer (Primary)
  • Indications Hyperphosphataemia; Renal failure
  • Focus Therapeutic Use

    • Most Recent Events

    • 23 Feb 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 29 Oct 2014 Design changed from open to randomizes, single blind, parallel; single arm to 2 arms; inclusion/ exclusion criterion changed; second arm is continuously changing between no arm to calcium carbonate, now it is placebo.
    • 01 Sep 2014 According to the ClinicalTrials.gov record, planned end date changed to 1 Nov 2014.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top